{
  "guideline": {
    "id": "PA166104984",
    "name": "Annotation of DPWG Guideline for phenytoin and CYP2C9",
    "source": "DPWG",
    "version": 32,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104984",
    "relatedChemicals": [
      {
        "id": "PA450947",
        "name": "phenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299256",
      "name": "Recommendation PA166299256",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061619,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 40% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299252",
      "name": "Recommendation PA166299252",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061615,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299255",
      "name": "Recommendation PA166299255",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061618,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299251",
      "name": "Recommendation PA166299251",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061614,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299249",
      "name": "Recommendation PA166299249",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061612,
        "html": "<p>The guideline does not provide a recommendation for phenytoin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on phenytoin."
      ],
      "lookupKey": {
        "CYP2C9": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299254",
      "name": "Recommendation PA166299254",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061617,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299250",
      "name": "Recommendation PA166299250",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061613,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2C9": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299253",
      "name": "Recommendation PA166299253",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061616,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 40-50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": [
        "Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2C9": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}